Biostatistics and real-world evidence expert joins global CRO to advance strategic analytics and accelerate drug development

Phastar, the global biometrics and data science-focused Contract Research Organization (CRO), has appointed Billy Amzal as Head of Strategic Consulting.

A statistician, public health scientist, and entrepreneur, Amzal brings more than 25 years of experience across the pharmaceutical, biotech, and health policy sectors. His expertise spans adaptive trial design, model-based meta-analysis, real-world evidence, Bayesian statistics, and predictive modelling—tools increasingly used to support regulatory and market access decision-making.

“Throughout his career, Billy has focused on turning methodological innovations into real-world value—connecting science, data, and strategy to drive better outcomes,” said Graham Clark, CEO of Phastar. “He brings an ecosystem-wide perspective that will help our teams unlock even greater value for clients through high-quality, innovative, and insight-driven approaches.”

Amzal has supported more than 100 regulatory and reimbursement submissions with advanced statistical analytics and serves as co-chair of the Statistics Special Interest Group at ISPOR. He is also an evaluation committee member for the European Commission on biomedical research funding and a statistical expert to agencies including the World Health Organization.

Prior to joining Phastar, Amzal was senior vice president at Certara and previously served as CEO of Quinten Health, an AI-enabled health analytics company. He will continue to collaborate with Quinten Health in a strategic capacity.

“It’s rare to find an organization of this scale with such a deep bench of innovation-driven, client-focused data scientists,” said Amzal.

“Phastar’s ability to bridge rigorous analytics with real-world business and public health impact was what drew me in. Strategic consulting can be truly transformative at a time when the life sciences industry is facing both complexity and unprecedented opportunity.”